{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Overall response rate (ORR) defined as a partial response (PR), very good partial response (VGPR), complete response (CR) or stringent CR (sCR). CR and sCR are defined in Outcome 2. VGPR requires: serum and urine M-protein detectable by immunofixation but not on electrophoresis OR \\>= 90% reduction in serum M-protein and urine M-protein \\<100 mg/24 h. If the only measurable disease is FLC, a \\>90% reduction in the difference between involved and uninvolved FLC levels. PR requires: if present at baseline, \\>= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>= 90% or to \\<200 mg/24hrs. If the only measurable disease is FLC, a ≥50% reduction in the difference between involved and uninvolved FLC levels. If the only measurable disease is BM, a ≥ 50% reduction in BM PCs (provided the baseline PCs was ≥ 30%). If present at baseline, ≥ 50% reduction in the size (SPD) of soft tissue plasmacytomas.","groups":[{"description":"Patients receive dexamethasone IV on days 1, 8, 15, and 22 of cycles 1-2 and IV on day 1 and PO on days 8, 15, and 22 of subsequent cycles and elotuzumab IV on days 1, 8, 15, and 22 of cycles 1-2 and day 1 of subsequent cycles. Patients also receive pomalidomide PO on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"proportion of participants"}